

VALUE & OUTCOMES SPOTLIGHT

MARCH/APRIL 2017 VOL. 3, NO. 2

VALUE & OUTCOMES SPOTLIGHT EDITORS & EDITORIAL BOARD

EDITOR-IN-CHIEF – David Thompson, PhD,
Real World Evidence & Insights, InVentivHealth,
Boston, MA, USA
David.Thompson@inventivhealth.com

CO-EDITORS – Murtuza Bharmal, PhD, Merck
KGaA, Germany; Benjamin Craig, PhD, University
of South Florida, USA

EDITORIAL BOARD – Syed Mohamed Aljunid,
PhD, United Nations University-International
Institute For Global Health, Malaysia; Soraya
Azmi, MBBS, MPH, Azmi Burhani Consulting,
Malaysia; Amit Chhabra, MD, MPH, Pfizer, Inc.,
USA; Benjamin Craig, PhD, H. Lee Moffitt Cancer
Center & Research Institute, USA; Yvonne Lee,
MPH, Pfizer, Malaysia; Martin Marciniak, PhD,
GlaxoSmithKline, USA; Axel C. Mühlbacher,
PhD, MBA, HS Neubrandenburg, Germany;
George Papadopoulos, BSc(Hons), Emerald
Corporate Group Pty., Ltd., Australia; Stephen
W. Schondelmeyer, PhD, University of Minnesota,
USA; Gabriela Tannus, MSc, Axia.Bio, Brazil;
Mondher Toumi, MD, PhD, MSc, University
Aix-Marseille/Creativ-Ceutical, France; Gergana
Zlateva, PhD, Pfizer, Inc., USA

MANAGEMENT ADVISORY BOARD – Nancy Devlin,
PhD, OHE, UK; Josephine Mauskopf, PhD, RTI
Health Solutions, USA; Gordon Liu, PhD

VALUE & OUTCOMES SPOTLIGHT PUBLISHING, SUBSCRIPTION, AND ADVERTISING OFFICE:

Value & Outcomes Spotlight
Print: ISSN 2375-866X
Online: ISSN 2375-8678
USPS: 019121

Published bi-monthly by:
ISPOR

505 Lawrence Square Blvd. South
Lawrenceville, NJ 08648 USA
Tel: 609-586-4981; Toll Free: 1-800-992-0643
Fax: 609-586-4982; Website: www.ispor.org

Periodicals Postage paid at Annapolis, MD 21401
and at additional mailing offices.

POSTMASTER: Send address changes to:

Value & Outcomes Spotlight
505 Lawrence Square Blvd., South
Lawrenceville, NJ 08648 USA

Managing Editor: Stephen L. Priori
email: spriori@ispor.org

Advertising Coordinator: Lyn Beamesderfer
email: lbeamesderfer@ispor.org

Direct photocopy permission and reprint requests
to Managing Editor.

© 2017 International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). All rights reserved under
International and Pan-American copyright conventions.

While *Value & Outcomes Spotlight* is designed to provide
accurate information regarding the subject matters covered, the
views, opinions, and recommendations expressed, are those of
the contributors and not of the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).

LETTER FROM THE EDITOR



The world is topsy-turvy in so many ways these days it's difficult to keep up. In sports, did the Chicago Cubs really win the World Series after 108 years of heartbreak, and did Leicester City really beat 5,000-to-1 odds to win the Premiership? In movies, did *La La Land* just win the Oscar for best picture or was it *Moonlight*? In politics, did ... well, let's not even go there.

In our realm we have our own topsy-turvy example to point to, in that after more than a century of real-world research driving changes in regulatory, we're now entering a period in which changes in regulatory are poised to drive real-world research. Consider how things have unfolded ...

One can identify influences of real-world research in the origins of the US Food & Drug Administration, beginning with the "muckraking" journalism of Upton Sinclair in the early 1900s, which exposed unsanitary conditions and harsh treatment of immigrant labor in America's meat packing plants (his classic novel, *The Jungle*, details it all). Later, in the 1930s, real-world research pinpointed the product, Elixir Sulfanilimide, as the cause of hundreds of deaths (mostly in children), leading to legislation allowing FDA (for the first time!) to require manufacturers to demonstrate product safety before obtaining marketing approval. And then in the 1960s it was real-world data linking severe birth defects to the drug, thalidomide, that led to further stiffening of regulatory requirements and demonstration of product safety and (for the first time!) efficacy for FDA approval. No one was talking about real-world data in those days but make no mistake in each of these examples that's exactly what was driving these changes in the regulatory apparatus.

Now, with the 21st Century Cures Act in the US and changes to clinical trial regulations in Europe, the tables have turned and it will be regulatory driving changes in the conduct of real-world research. Cures, passed in December 2016, encompasses a variety of provisions "to accelerate the discovery, development and delivery of 21st century cures" in the US. Included among these provisions are instructions for FDA to consider real-world evidence as a potential factor in approval and labeling decisions. In Europe, new regulations on clinical trials include a new category for the "low-intervention clinical trial," with streamlined safety monitoring requirements versus conventional randomized controlled trials. By all appearances, it seems this new category is intended to be occupied by the pragmatic clinical trial, the real-world analog to the conventional RCT. Provisions from these new regulations in the US and Europe are being phased in over time, so their immediate impact may be minimal. But it will be interesting to see how these regulations, which on paper clearly favor expanded conduct of real-world research, change the nature of the work we do in the years ahead. It's a topsy-turvy situation to think about.

You know what else is topsy-turvy? For the first time ever, ISPOR is coming to Boston! This issue of *Value & Outcomes Spotlight* should arrive in your inbox just as you're making final preparations for the 22nd Annual International Meeting in May.

See you there!

Sincerely,

David Thompson, PhD
Editor-in-Chief, *Value & Outcomes Spotlight*

Tell us what you think of *Value & Outcomes Spotlight*! Send feedback to vos@ispor.org or use the comments form at <http://www.ispor.org/ValueOutcomesSpotlight/CommentForm>